NR3C2 and Hyperkalemia: Individual studies report various effects on plasma potassium concentrations following MR blockade, including no difference between placebo and treatment (Epstein et al., 2006; Gonzales Monte et al., 2010; Sato et al., 2003) and increased hyperkalaemia incidence (Ando et al., 2014; Bianchi et al., 2006; Chrysostomou et al., 2006; Pisoni et al., 2012; Quach et al., 2016; Rachmani et al., 2004).